The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Centre For Research Excellence To Transform Outcomes Of Critically Ill Patients In ICU (CRE-ICU)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
Patients who are admitted to intensive care (ICU) and require mechanical ventilation for life support account for 63,000 ICU admissions and 8,190 deaths each year in Australia, higher than the national road toll. CRE-ICU will transform outcomes for these patients by using data within registries and electronic medical records to perform high-impact, low cost clinical trials, generating new knowledge to inform national guidelines and policies and training the next generation of researchers.
A Multi-centre RCT Of An Open Lung Strategy Including Permissive Hypercapnia, Alveloar Recruitment, And Low Airway Pressure In Patients With ARDS
Funder
National Health and Medical Research Council
Funding Amount
$1,041,070.00
Summary
Acute respiratory distress syndrome (ARDS) is a severe inflammatory condition of the lungs that complicates many critical illnesses and is associated with high mortality. Inappropriate settings of the mechanical ventilator can lead to a worsening outcome. The aim of this Phase II study is to compare the clinical efficiency of a novel ventilation strategy to reduce the duration of mechanical ventilation in survivors, including several lung protective settings, to that of current standard care.
The Prophylactic Hypothermia To Lessen Traumatic Brain Injury-randomised Controlled Trial : Continuation Of Funding Request
Funder
National Health and Medical Research Council
Funding Amount
$266,321.00
Summary
Traumatic brain injury (TBI) is a major cause of death and long term disability. About half with severe TBI will die or have a poor outcome. The social and economic costs to the community are high. Treatment focuses on optimising oxygen and blood flow to the brain. Cooling may protect the brain. POLAR is a randomised trial of early cooling in patients with TBI. Cooling is started within 3 hours of injury. Data about the injury management and safety is collected. Recovery is measured at 6 months.
Predicting The Risk Of Invasive Candidiasis In Critically Ill Patients
Funder
National Health and Medical Research Council
Funding Amount
$1,258,287.00
Summary
Invasive fungal infections (such as bloodstream infections) are a serious and increasing problem for critically ill patients managed in the Intensive Care Unit. Outcomes can be improved by giving early treatment only to those at highest risk of fungal infection. Our aim is to easily identify those at high-risk. Patients treated in seven major ICUs will be observed and a simple and accurate method of scoring their illness characteristics and amount-types of fungi present will be developed.
Improved Early Respiratory Support Of Infants And Children
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Worldwide respiratory disease in children has the highest health care burden on society. Children aged <5 years in particular, are increasing in hospital admissions and to intensive care where the cost is elevated. New ways of oxygen therapy have been studied and shown that we can reduce ICU admission if a therapy known as Nasal High Flow (NHF) therapy is applied earlier in the progression of the disease. Further research is needed in NHF therapy and to improve upon our patient outcomes.
Understanding The Mechanisms Of Bleeding And Clotting Complications For Children On Extracorporeal Circuits.
Funder
National Health and Medical Research Council
Funding Amount
$1,113,385.00
Summary
Extracorporeal Membrane Oxygenation (ECMO) is advanced life support, which can save critically ill children. Significant bleeding occurs in 39%; clotting in 31% of children on ECMO; stroke in 12%. The biggest barrier to reducing these complications is the lack of understanding of how the bleeding/clotting system works in ECMO. This unique proposal uses the largest paediatric ECMO population in Australia and a multidisplinary expert team to develop a mechanistic understanding of these issues.
The Australasian Resuscitation In Sepsis Evaluation - Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,424,807.00
Summary
Patients with severe infections often present to Emergency Departments and early treatment with particular fluids, blood transfusions and stimulants, may improve survival rates. To determine whether early treatment is safe and effective in reducing deaths, the Australian and New Zealand Intensive Care Society Clinical Trials Group, in conjunction with the Australasian College of Emergency Medicine, plan to perform a large trial of early goal directed therapy in patients with severe infections.
The Cost-effectiveness Of Early Resuscitation Of Sepsis In Australia - An Economic Evaluation Alongside The ARISE-RCT
Funder
National Health and Medical Research Council
Funding Amount
$115,971.00
Summary
Critical care treatment is expensive and consumes a significant portion of hospital resources. This study will collect cost, survival and quality of life data on a group of sepsis patients enrolled in a trial of strict protocolised treatment versus standard care (the ARISE study). This information will be used to determine how much it costs for each additional survivor with protocolised treatment, and how much it costs for each quality adjusted life year gained with protocolised treatment.
Re-EValuating The Inhibition Of Stress Erosions (REVISE): Gastrointestinal Bleeding Prophylaxis In ICU
Funder
National Health and Medical Research Council
Funding Amount
$2,955,164.00
Summary
Around 50,000 patients in Australian Intensive Care Units receive a drug called pantoprazole each year with the aim of preventing bleeding from the gut. Recent research suggests this practice is ineffective and may harm patients by increasing their risk of serious infections. We will perform a definitive study to determine whether the widespread use of pantoprazole is beneficial or harmful.